The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus
concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in
participants with locally advanced cervical cancer.
The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior
to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and
Once the study objectives have been met or the study has ended, participants will be
discontinued from this study and will be enrolled in an extension study to continue
protocol-defined assessments and treatment.
Disorders of cervix NOS,
External Beam Radiotherapy (EBRT),
Placebo for Pembrolizumab
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.